

## **moksha8 Expands Alliance with Roche to Commercialize \$200 Million of Products in Brazil and Mexico**

**Mexico City, Sao Paulo, Philadelphia, – May 20, 2009 /PR Newswire**

moksha8, Inc. announced today that it has expanded its strategic partnership with Roche to commercialize an additional portfolio of products in Mexico currently generating sales of \$140 million USD.

moksha8 will commercialize products in three therapeutic areas, CNS disease, anti-infectives, and inflammation. The product portfolio consists of well-known brands including Rivotril<sup>®</sup>, Rocephin<sup>®</sup> and Bactrim<sup>®</sup>.

“moksha8 has produced strong results for Roche in Brazil and we are delighted to expand our relationship to include Mexico as a key country in Latin America” said Ernest Egli, President of Roche Latin America. “moksha8 brings strong commercial capabilities and innovative marketing to our CNS, anti-infectives and inflammation franchises. We look forward to continuing this valuable relationship.”

“moksha8 has established a broad footprint in Latin America with leading products that are cornerstones of medical care,” said Simba Gill, CEO of moksha8. “We look forward to continuing our strong relationship with Roche and driving value from this important portfolio of products. We are now firmly positioned as the leading partner of choice for pharmaceutical and biotechnology companies looking to generate value across Latin America.”

In just over a year, moksha8 has grown its commercial organization to over 200 employees in Brazil and Mexico and a portfolio of products with sales of \$200 million USD. moksha8 is uniquely positioned as the leading specialty pharmaceutical company in Latin America with a strong presence in CNS, anti-infectives and inflammation.

moksha8 was founded in December 2006 by Simba Gill and Texas Pacific Group, and has raised significant financing from top-tier private equity firms, including Texas Pacific Group and Votorantim Novos Negocios, the venture capital and private equity arm of Votorantim, one of Brazil's largest privately held conglomerates. moksha8 is uniquely positioned as the partner of choice for both pharmaceutical and biotechnology companies seeking to capture value from their products in high growth emerging markets. moksha8 has established commercial operations in key geographies in Latin America including Sao Paulo and Mexico City, with corporate offices in Pennsylvania. moksha8 provides the highest quality medicines to the fastest growing markets of the world.

**For more information, please contact:**

Investor and Media Relations

Jeannine Medeiros

+852 9191 0375

Email: [jeannine@moksha8.com](mailto:jeannine@moksha8.com)